Sign in
CompletedPhase 3

A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Key facts

Who runs it
Helixmith Co., Ltd.
Where
Chesterfield, Clearwater, Houston, Little Rock, Los Angeles, Manassas, McAllen, Norfolk, O'Fallon, Phoenix, Rapid City, Richmond, Sacramento, Springfield, Staten Island, and Waxahachie, United StatesSee the 16 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
106 people enrolled
Started
17 May 2021
Ended
23 Jul 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Engensis
  • Placebo
Record updated
9 October 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Completed study VMDN-003-2 and consent to enroll in study VMDN-003-2b

Who cannot take part

  • None

Where in United States

  • Clinical Research ProfessionalsChesterfield, United States
  • Innovative Research of West Florida, Inc.Clearwater, United States
  • Nerve and Muscle Center of TexasHouston, United States
  • Clinical Trials - Little RockLittle Rock, United States
  • California Medical Clinic for HeadacheLos Angeles, United States
  • Manassas Clinical Research CenterManassas, United States
  • Futuro Clinical TrialsMcAllen, United States
  • Eastern Virginia Medical SchoolNorfolk, United States
  • Gateway Clinical Trials, LLCO'Fallon, United States
  • Arizona Research CenterPhoenix, United States
  • Health ConceptsRapid City, United States
  • Dominion Medical AssociatesRichmond, United States
  • Clinical Trials Research SacramentoSacramento, United States
  • Foot & Ankle Center of IllinoisSpringfield, United States
  • Richmond Behavioral AssociatesStaten Island, United States
  • ClinPoint Trials LLCWaxahachie, United States

About the trial

What the trial wants to find out

To evaluate the durability of efficacy and long-term safety of intramuscular administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.

The 2 groups in the trial

  • EngensisTreatment being tested

    Patients who have received Engensis in protocol VMDN-003-2

  • PlaceboPlacebo, for comparison

    Patients who have received Placebo in protocol VMDN-003-2

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A 6-Month Extension Study Following Protocol VMDN-003-2 - An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Record updated
9 October 2025